预约演示
With deal to buy 7 Recipharm plants, private equity firm Blue Wolf plans new CDMO
2024-04-02
并购疫苗引进/卖出
CDMO Recipharm has agreed to sell seven facilities in Europe to U.S. private equity firm Blue Wolf Capital.
Another sign that the post-pandemic reshaping of the CDMO industry isn't over came TuesdaBlue Wolf Capitalector’s most powerful companies, Recipharm, sold off seven of its manufacturing and development facilities in Europe to Blue Wolf Capital.
The U.S. private equity firm has purchased plants in Parets, Spain; Pessac, France; and five in Recipharm’s home country of Sweden. The SweRecipharms are in Hoganas, Karlskoga, Solna, Strangnas and Uppsala.Blue Wolf Capital
It is another divestment in the remake of Recipharm. Also on Tuesday, the Stockholm-based companRecipharmed the spinout of its inhaler business, which includes three plants.
Recipharm has said it wants to expand its biologics production capacity and position itself to take advantage of the increasing demand for cell and gene therapies.
Recipharmal with Blue Wolf, each of the seven facilities has been run by Recipharm for at least a decade. The plants are focused on the development of oral solid, semi-solid and liquid dosage products and serve more than 120 customers worldwide, Recipharm said.
Recipharm opened the year with 25 facilities in 10 countries. It has two biologic manufacturing sites in Massachusetts, which are its lone locations in the U.S. It also has four standalone facilities for development and manufacturing in Bengaluru, India, and a development lab in Israel. The rest of its sites are in Europe, with four each in Italy and Germany.
Recipharm’s push to transform was apparent in 2022 when it sold an active pharmaceutical ingredients plant in England to Pharmaron of China and a capsule and tablet production facility in France to Astrea. Meanwhile, Recipharm also pulled off acquisitions of Vibalogics of Germany, GenIbet of Portugal and Arranta Bio of Watertown, Massachusetts.
Recipharme pandemic, Recipharm made a big score partnering with Moderna to produce its COVID-19 vaccines. In 2022, ReciphPharmaronenue skyrocketed by 30% to a company record 13,669 Swedish krona ($1Astreallion).RecipharmVibalogicsGenIbetArranta Bio
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。